Is there a high-risk subgroup of stage i epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?

Jamie N. Bakkum-Gamez, Debra L. Richardson, Leigh G. Seamon, Giovanni D. Aletti, Cecelia A. Powless, Gary L. Keeney, David M. O'Malley, William A. Cliby

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Is there a high-risk subgroup of stage i epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?'. Together they form a unique fingerprint.